Rolling my suitcase up the street at the conclusion of American Society of Clinical Oncology (ASCO) conference on Monday, I reflected on the huge number of steps my fitbit registered across the four day meeting in Chicago. Many tens of thousands of steps had been logged, and certainly my sore feet told me that was true!
More important than the number of steps I had walked throughout the conference was the number of hands I had shaken in greeting over that time.
Physicians, students, researchers and service providers converged this week on Chicago for the 2018 meeting of the American Association for Cancer Research. Overall attendance at the conference was nearly 17,000. Even bone-chilling wind and snow could dampen the enthusiasm for this much-anticipated event.
The AACR conference covers every aspect of cancer research and treatment, from basic information all the way to presentations about futuristic treatments currently being developed. World class scientists took to the podium and the jammed hallways to share their research and forge personal and professional alliances.
In this interview blog, Stephanie Langouet, Cmed’s Sr Vice President of CRO Operations, shares some of the challenges of drug development and research for rare diseases in children. She hopes that by sharing and properly collaborating we can all contribute to a better future for those who suffer from a rare disease.
What is a rare disease and why should they be studied? A rare disease is any disorder that affects a small percentage of the population.
Both the Loader and Review apps are part of Cmed’s encapsia® clinical data suite, the first cloud-based suite of apps for the collection, management and analysis of clinical trial data.
The Loader app streamlines the process for third party data uploads. It can be configured with automated transfer rules so that the data can be automatically loaded into the encapsia® database where it can be viewed, reconciled and managed in the Review app.